诺西那生钠治疗脊髓性肌萎缩症效果的meta分析

Meta-analysis on efficacy of Nosenazone sodium in treatment of patients with spinal muscular atrophy

目的采用meta分析验证诺西那生钠治疗脊髓性肌萎缩症(spinal muscular atrophy,SMA)的有效性。方法以诺西那生纳治疗的SMA患者为研究对象,系统检索2016年1月至2023年6月期间的维普数据库、中国知网、万方数据库、PubMed等数据库,采用RevMan5.7统计软件进行meta分析,合并国内外病例,系统分析诺西那生钠治疗SMA的有效性。结果纳入11篇文献,共232例SMA患者。SMA患者使用诺西那生钠治疗后健康改善的危险度差为0.67,95%CI 0.39~0.96。结论诺西那生钠治疗SMA效果显著。

Objective To verify the effectiveness of Nosenazone sodium in the treatment of patients with spinal muscular atrophy(SMA)by meta-analysis.Methods The study objects were the patients with SMA treated by Nosenazone sodium.The databases,such as VIP Database,China National Knowledge Infrastructure,Wanfang Database,PubMed,et.,were systematically searched from January 2016 to June 2023.RevMan5.7 was used to do the meta-analysis.The effectiveness of Nosenazone sodium for the domestic and foreign cases of SMA was systematically analyzed.Results A total of 232 patients with SMA were included in 11 literatures.The risk difference for improvement in SMA patients treated by Nosenazone sodium was 0.67(95%CI 0.39-0.96).Conclusion Nosenazone sodium for patients with SMA is obviously effective.